Immunovant, Inc. Stock News

The most overbought stocks in the healthcare sector presents an opportunity to go short on these overvalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when p

Merck, Vertex Pharmaceuticals, Immunocore Holdings and Immunovant are part of the Zacks top Analyst Blog.

Here are four drug companies, MRK, VRTX, IMCR and IMVT, that are up 40% or more in 2022 so far and still have room for growth in 2023.

Here are four drug companies, MRK, VRTX, IMCR and IMVT, that are up 40% or more in 2022 so far and still have room for growth in 2023.

Here is how Immunovant, Inc. (IMVT) and McKesson (MCK) have performed compared to their sector so far this year.

Here is how Immunovant, Inc. (IMVT) and McKesson (MCK) have performed compared to their sector so far this year.

Here is how BioVie Inc. (BIVI) and Immunovant, Inc. (IMVT) have performed compared to their sector so far this year.

Immunovant (IMVT) is progressing well with its lead pipeline candidate batoclimab being developed for treating myasthenia gravis, thyroid eye disease and other autoimmune diseases.

Immunovant (IMVT) is progressing well with its lead pipeline candidate batoclimab being developed for treating myasthenia gravis, thyroid eye disease and other autoimmune diseases.

Immunovant (IMVT) is making good progress with its lead pipeline candidate, batoclimab, which is being developed for treating myasthenia gravis, thyroid eye disease and other autoimmune diseases.

Immunovant (IMVT) is making good progress with its lead pipeline candidate, batoclimab, which is being developed for treating myasthenia gravis, thyroid eye disease and other autoimmune diseases.

Here is how BioVie Inc. (BIVI) and Immunovant, Inc. (IMVT) have performed compared to their sector so far this year.

Within the last quarter, Immunovant (NASDAQ:IMVT) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 3 1 2 0 0 Last 30D

Over the past 3 months, 6 analysts have published their opinion on Immunovant (NASDAQ:IMVT) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a comp

Immunovant's (IMVT) earnings meet estimates in the fiscal second quarter ending Sep 30, 2022. IMVT deepens focus on developing its lead candidate batoclimab.